PRIME-EMD-PMD

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
34 patients (estimated)
Tags
Bispecific Antibody, T Cell Engager (TCE), B-Cell Maturation Antigen (BCMA)
Trial Type
Treatment
Last Update
SparkCures ID
2249
NCT Identifier
NCT07382739

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.